Verastem, Inc. to Present at Keystone Symposia on PI3 Kinase
Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of data at the Keystone Symposia on “PI3-Kinase and Interplay with Other Signaling Pathways” being held February 24 – March 1, 2013, in Keystone, Colorado.